Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial infarction volume-related outcomes in cardiac catheterization laboratory and, 291 294 ADMIRAL trial, 182 ADVANCE trial, 184 American College of Cardiology/American Heart Association recommendations for coronary intravascular ultrasound, 168 170 American College of Cardiology/American Heart Association task force on lesion morphology, 153 154, 155 AMIGO trial, 203 Angina CABG vs. percutaneous coronary interventions for, 256 261 Angiography quantitative coronary Angioplasty balloon cutting, 205 FXminiRAIL, 206 excimer laser coronary, 206 AngioSculpt scoring balloon, 206 207 Angio-Seal closure device, 281, 282 ANTHEM-TIMI trial, 191 Anticoagulant(s) in PCI, 186 190 direct thrombin inhibitors, 189 190 LMWH, 187 189 UFH, 186 189 Antiplatelet agents in PCI, 186 abciximab, 180 182 aspirin, 175 176 eptifibatide, 182 183 platelet ADP receptor antagonists, 176 180 platelet glycoproteiniib/iiia receptor antagonists, 180 tirofiban, 183 186 Antithrombotic therapy in PCI, 175 199. See also specific agents, e.g., Antiplatelet agents, in PCI. anticoagulants, 186 190 antiplatelet agents, 186 clinical trials of, 175 199 acronyms for trial names, 191 193 fondaparinux, 190 191 novel agents, 190 191 ARMYDA-2 trial, 179 Artery(ies) anatomy of normal, 163 ASPIRE trial, 190 191 Aspirin in PCI, 175 176 Atherectomy, 201 202 directional coronary, 202 203 rotational, 203 204 Atherosclerosis described, 201 treatment of PCI related, 201 215 Atherotomy, 201 202 0733-8651/06/$ - see front matter Ó 2006 Elsevier Inc. All rights reserved. doi:10.1016/s0733-8651(06)00040-3 cardiology.theclinics.com
300 INDEX B Balloon angioplasty cutting, 205 FXminiRAIL, 206 BAT trial, 190 Biolimus A-9-eluting stent, 224 C CABG. See Coronary artery bypass grafting (CABG). CACHET trial, 190 CADILLAC trial, 182 CAPTURE trial, 181 Cardiac catheterization laboratory quality in described, 287 identification of, 287 quality management in volume-related outcomes related to, 287 297 acute myocardial infarction experience with, 291 294 current experience with, 289 291 described, 288 longitudinal studies, 294 295 PTCA and, 289 surgical experience with, 288 289 CHARISMA trial, 180 Chito-Seal pad in vascular closure, 278 Chronic total coronary occlusions (CTOs), 247 254 histopathology of, 248 treatment of indications for, 247 248 non-guidewire novel devices in, 251 outcomes of, 252 patient selection for, 248 techniques in, 251 CLASSICS trial, 177 Clopidogrel in PCI, 177 180 Closure devices vascular, 277 286. See also Vascular closure devices. Coronary angiography quantitative Coronary angioplasty excimer laser, 206 Coronary artery(ies) left main evaluation of intravascular ultrasound in, 165 Coronary artery bypass grafting (CABG), 255 percutaneous coronary interventions vs. implications in patient management, 262 in angina patients, 256 261 randomized trials comparing limitations of, 261 262 stenting vs., 258 261 Coronary bifurcation lesions, 233 246 anatomic classification of, 233 236 guiding catheter in selection of, 236 impossible side branch access, 235 236 isolated ostial lesions involving mail vessel or side branch, 233 of main vessel, 234 of side branch, 234 235 stents for crush technique, 240 242 culottes technique, 242 243 future directions in, 244 246 implantation of lesion preparation for, 243 244 number of, 236 243 one stent by intention to treat, 236 237 pharmacotherapy with, 244 reverse crush technique, 242 simultaneous kissing stents technique, 237 240 T technique, 242 two stents by intention to treat, 237 V stent technique, 237 Y technique, 243 Coronary occlusion total, 157 CREDO trial, 177, 180 CRUISE trial, 188 C-SIRIUS trial, 219 CTOs. See Chronic total coronary occlusions (CTOs).
INDEX 301 CURE trial, 177, 178 Cutting balloon angioplasty, 205 D Debulking devices, 201 202 Degenerated saphenous vein grafts, 155 156 DESIRE trial, 203 Direct thrombin inhibitors in PCI, 189 190 Directional coronary atherectomy, 202 203 DISPERSE-2 phase II trial, 179 180 Distal protection devices, 210 213 Doppler ultrasound intracoronary 161 Drug-eluting stents, 217 231 cost-effectiveness of, 226 durable polymer, paclitaxel-eluting stents, 220 222 failed or minimally effective, 224 225 ongoing programs, 223 224 outstanding issues related to, 225 226 restenosis after predictors of, 226 sirolimus-eluting stents, 217 219 thrombosis related to, 225 226 D-Stat products in vascular closure, 278 Duett closure device, 283 284 E EDRES trial, 204 Endeavor trials, 223 EPIC trial, 181 EPILOG trial, 180 181, 188 EPISTENT trial, 181, 186, 188 Eptifibatide in PCI, 182 183 E-SIRIUS trial, 218 ESPRIT trial, 183, 186 Everolimus-eluting durable polymer stent, 224 Excimer laser coronary angioplasty, 206 F FANTASTIC study, 177 FFR. See Fractional flow reserve (FFR). Fondaparinux in PCI, 190 191 Fractional flow reserve (FFR) in lesion severity evaluation, 161 FXminiRAIL balloon angioplasty, 206 H HELVETICA trial, 189 Heparin(s) LMWH in PCI, 187 189 UFH in PCI, 186 189 HORIZONS trial, 190 I IABP. See Intra-aortic balloon pump (IABP). IMPACT-II trial, 183 Impella CardioSystems, 270 274 complications of, 273 274 contraindications to, 272 described, 6 7 hemodynamic effects of, 273 implantation of, 272 273 INTERACT trial, 188 Intra-aortic balloon pump (IABP), 266 Intracoronary ultrasound Doppler in lesion severity evaluation, 159 161 Intravascular ultrasound American College of Cardiology/American Heart Association recommendations for, 168 170 arterial measurements by, 163 complications of assessment of, 168 170 for stent restenosis, 170 for stenting guidance, 165 168 future of, 170 171 in coronary lesion evaluation, 163 165 in left main coronary artery evaluation, 165
302 INDEX Intravascular (continued) in percutaneous coronary interventions era, 163 173. See also Percutaneous coronary interventions, intravascular ultrasound in era of. vulnerable plaque identification with, 170 171 ISAR diabetes trial, 222 ISAR-2 trial, 182 ISAR-DESIRE trial, 222 223 ISAR-REACT trial, 179, 182 ISAR-SWEET trial, 181 J JUMBO-TIMI 26 trial, 179 L Laser therapy, 201 202 Left main coronary artery evaluation of intravascular ultrasound in, 165 Left ventricular assist devices (LVADs), 265 275. See also specific types, e.g., TandemHeart IABP, 266 Impella CardioSystems, 270 274 intra-aortic balloon pump, 266 TandemHeart, 266 270 Lesion(s) angulated, 154 bifurcation, 154 calcification of, 154 155 classification of, 153 162 degenerated saphenous vein grafts, 155 156 eccentric, 156 inaccessible, 156 irregular, 156 long, 156 morphology of American College of Cardiology/American Heart Association task force on, 153 154, 155 ostial, 157 severity of evaluation of, 159 161 LMWH. See Low molecular weight heparin (LMWH). Low molecular weight heparin (LMWH) in PCI, 187 189 LVADs. See Left ventricular assist devices (LVADs). M Myocardial infarction acute volume-related outcomes in cardiac catheterization laboratory and, 291 294 N NICE-1 trial, 188 P Paclitaxel derivative-eluting polymeric sleeve, 225 Paclitaxel spray stents, 224 225 Paclitaxel-eluting stents durable, polymer, 220 222 PARAGON trials, 186 Patch(es) vascular closure related, 277 278 PCI. See Percutaneous coronary interventions (PCIs). PCI-CURE trial, 180 Perclose Prostar in vascular closure, 278 279 Percutaneous coronary interventions (PCIs), 201 215, 255 263. See also specific types AngioSculpt scoring balloon, 206 207 antithrombotic therapy in, 175 199. See also specific agents, e.g., Antiplatelet agents, in PCI. atherectomy, 201 202 atherotomy, 201 202 CABG vs. implications in patient management, 262 in angina patients, 256 261 randomized trials comparing limitations of, 261 262 cutting balloon angioplasty, 205 debulking devices, 201 202 directional coronary atherectomy, 202 203 distal protection devices, 210 213 excimer laser coronary angioplasty, 206 FXminiRAIL balloon angioplasty, 206 history of, 255 256
INDEX 303 intravascular ultrasound in era of, 163 173. See also Intravascular ultrasound. laser therapy, 201 202 LVADs, 265 275 rotational atherectomy, 203 204 SilverHawk System, 206 207 thrombectomy devices, 207 210 Percutaneous transluminal coronary angioplasty (PTCA) volume-related outcomes in cardiac catheterization laboratory and, 289 PISCES program, 223 224 Platelet(s) biology of, 175 Platelet ADP receptor antagonists in PCI, 176 180 Platelet glycoproteiniib/iiia receptor antagonists in PCI, 180 PRISM-PLUS trial, 184 PROXIMATE-TIMI 27 trial, 191 PTCA. See Percutaneous transluminal coronary angioplasty (PTCA). PURSUIT trial, 182 Q Quality management in cardiac catheterization laboratory volume-related outcomes related to, 287 297. See also Cardiac catheterization laboratory, quality management in, volume-related outcomes related to. Quantitative coronary angiography R RAPPORT trial, 182 RAVEL trial, 218 REALITY trial, 222 REPLACE-1 trial, 190 REPLACE-2 trial, 190 RESTORE trial, 184 Rotational atherectomy, 203 204 S Saphenous vein grafts degenerated, 155 156 Scion Clo-Syr P.A.D. in vascular closure, 278 Sealant closure devices, 281 SilverHawk System, 206 207 SIRIUS registries and subset analyses, 219 220 SIRIUS trial, 218 Sirolimus-eluting stents, 217 220 SIRTAX trial, 222 SPORT trial, 204 Staple-mediated closure device, 284 285 STEEPLE trial, 188 Stent(s) actinomycin D-eluting, 224 Biolimus A-9-eluting, 224 drug-eluting, 217 231. See also Drug-eluting stents. everolimus-eluting durable polymer, 224 for coronary bifurcation lesions, 236 243. See also Coronary bifurcation lesions, stents for. paclitaxel spray, 224 225 paclitaxel-eluting durable, polymer, 220 222 restenosis of intravascular ultrasound for, 170 sirolimus-eluting, 217 220 Stenting CABG vs., 258 261 intravascular ultrasound in, 165 168 Suture-mediated closure devices, 278 SYNERGY trial, 189 Syveck Patch in vascular closure, 277 278 T TandemHeart, 266 270 applications of, 270 complications of, 269 270 contraindications to, 268 described, 266 268 explantation of, 269 hemodynamic effects of, 269 implantation of, 268 269 subsystems of, 266 268 TARGET trial, 185 TAXI trial, 222
304 INDEX TandemHeart (continued) TAXUS registries and subset analyses, 221 222 TAXUS-I trial, 220 TAXUS-II trial, 220 TAXUS-III trial, 220 TAXUS-IV trial, 220 221 TAXUS-V trial, 221 TAXUS-VI trial, 221 Thienopyridine antiplatelet agents in PCI, 176 177 Thrombectomy devices, 207 210 Thrombin inhibitors direct in PCI, 189 190 Thrombosis(es) drug-eluting stents and, 225 226 Thrombus(i), 157 159 Ticlopidine in PCI, 177 Tirofiban in PCI, 183 186 Total coronary occlusion, 157 TRITON-TIMI 38 trial, 179 U UFH. See Unfractionated heparin (UFH). Ultrasound Doppler intracoronary in lesion severity evaluation, 159 161 intravascular in percutaneous coronary interventions era, 163 173. See also Intravascular ultrasound. Unfractionated heparin (UFH) in PCI, 186 189 V Vascular closure devices, 277 286 Angio-Seal, 281 complications associated with, 285 Duett, 283 284 patches, 277 278 Perclose Prostar, 278 279 sealant closure devices, 281 staple-mediated, 284 285 suture-mediated, 278 Vasoseal, 281, 283 X-Site suture, 279 280 Vasoseal closure device, 281, 283 Vein grafts saphenous degenerated, 155 156 X XaNADU-ACS trial, 191 X-Site suture closure device in vascular closure, 279 280